Boston Scientific Co. (NYSE:BSX - Get Free Report) Director Edward J. Ludwig sold 9,818 shares of the business's stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $73.29, for a total value of $719,561.22. Following the completion of the sale, the director now owns 41,374 shares of the company's stock, valued at $3,032,300.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Boston Scientific Stock Performance
NYSE:BSX opened at $72.48 on Tuesday. The company's 50-day moving average is $67.96 and its two-hundred day moving average is $60.80. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $74.39. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82. The firm has a market capitalization of $106.34 billion, a price-to-earnings ratio of 60.91, a PEG ratio of 2.52 and a beta of 0.78.
Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, beating the consensus estimate of $0.51 by $0.04. The firm had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.59 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.63%. During the same quarter in the previous year, the company earned $0.45 EPS. Analysts forecast that Boston Scientific Co. will post 2.32 EPS for the current year.
Institutional Inflows and Outflows
Elon to Transform U.S. Economy?
From Porter & Company | Ad
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites.
And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
One company holds a near-total monopoly on it.
Institutional investors have recently made changes to their positions in the business. Bruce G. Allen Investments LLC purchased a new position in Boston Scientific in the 4th quarter valued at approximately $28,000. Northwest Investment Counselors LLC acquired a new stake in shares of Boston Scientific in the first quarter valued at $31,000. Sachetta LLC purchased a new position in Boston Scientific in the fourth quarter valued at $32,000. Frazier Financial Advisors LLC acquired a new position in Boston Scientific during the 4th quarter worth $32,000. Finally, Jones Financial Companies Lllp increased its holdings in Boston Scientific by 53.0% during the 4th quarter. Jones Financial Companies Lllp now owns 557 shares of the medical equipment provider's stock worth $32,000 after purchasing an additional 193 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.
Analyst Ratings Changes
Several equities research analysts recently commented on the stock. Raymond James boosted their price target on shares of Boston Scientific from $73.00 to $85.00 and gave the stock a "strong-buy" rating in a report on Thursday, April 25th. Argus raised their price target on shares of Boston Scientific from $69.00 to $80.00 and gave the company a "buy" rating in a research note on Wednesday, April 3rd. TD Cowen boosted their price objective on Boston Scientific from $65.00 to $77.00 and gave the stock an "outperform" rating in a research note on Thursday, March 7th. Royal Bank of Canada raised their target price on Boston Scientific from $78.00 to $82.00 and gave the company an "outperform" rating in a research report on Thursday, April 25th. Finally, Evercore ISI boosted their price target on Boston Scientific from $72.00 to $78.00 and gave the stock an "outperform" rating in a research report on Thursday, April 25th. Three equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $75.09.
Check Out Our Latest Report on Boston Scientific
About Boston Scientific
(
Get Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
